黄芪丹参滴丸治疗冠心病心绞痛的临床研究  

Clinical Study of Huangqi Danshen Drop Pill for Angina Pectoris Due to Coronary Heart Disease

作　　者：张琼[1] 李立志[1] 涂秀华[1] 

机构地区：[1]中国中医研究院西苑医院,北京100091

出　　处：《中药新药与临床药理》2005年第4期288-290,共3页Traditional Chinese Drug Research and Clinical Pharmacology

摘　　要：目的评价黄芪丹参滴丸治疗冠心病心绞痛(气虚血瘀证)的临床疗效和安全性。方法采用随机、双盲双模拟、阳性药平行对照、多中心临床研究方法,将209例受试者分试验组104例(黄芪丹参滴丸),对照组105例(养心氏片)。结果黄芪丹参滴丸治疗心绞痛的显效率为43.27%,总有效率为86.53%;对中医症状的总有效率92.31%,黄芪丹参滴丸组优于对照组(P<0.01)。结论黄芪丹参滴丸治疗冠心病心绞痛(气虚血瘀证)疗效确切,未发现毒副作用。Objective To evaluate the therapeutic effect and safety of Huangqi Danshen Drop Pill (HDP) for angina pectoris (AP) due to coronary heart disease (CHD) classified as qi- deficiency and blood- stasis syndrome. Methods A multi- center, randomized, double- blind, double- simulation, positive- controlled, parallel group trial was adopted. 209 cases of AP due to CHD classified as qi- deficiency and blood- stasis syndrome were enrolled in this study: 104 in HDP group and 105 in Yangxinshi Tablets group. Results The markedly effective rate was 43.27 % , total effective rate 86.53 % , and total effective rate in improving TCM symptoms 92.31 % in HDP group, which were better than those in Yangxinshi Tablets group(P < 0.01). Conclusion HDP has definite effect for the treatment of AP due to CHD classified as qi- deficiency and blood- stasis syndrome, having no toxic and side effects.

关 键 词：黄芪丹参滴丸 冠心病心绞痛 中药疗法 

分 类 号：R285.6[医药卫生—中药学]